Please select the option that best describes you:
In which Her2+ breast cancer patients would you recommend extended adjuvant therapy with neratinib?
The FDA recently approved neratinib based on data from the ExteNET trial; however, benefit appears modest and the risk of toxicity is not low.
Answer from: Medical Oncologist at Community Practice
The benefit is largely in estrogen receptor positive patients and the gains are modest. Although with extensive and extended anti-diarrheal medications the almost intractable diarrhea seen with this agent can be made tolerable. On the other hand, it would take a VERY motivated patient, probably with...
Sign in or Register to read more